secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2026-06-15T11:02:38+00:00
Accession:  0001493152-26-028610
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals reports positive bioequivalence for undisclosed anticonvulsant generic drug
--------------------------------------------------------------------------------

- Pivotal BE study successful; generic product bioequivalent to branded anticonvulsant under fasting conditions.
- IQVIA reports $840M combined branded and generic sales for the 12 months ending April 2026.
- Elite to compile data and file ANDA with FDA; no specific timeline provided.
- Study was open-label, randomized, single-dose crossover in healthy adult subjects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315226028610/0001493152-26-028610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315226028610/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-028610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer